Epistaxis Clinical Trial
Official title:
Treatment of Nasal Staphylococcus Aureus Colonization in Patients With Hereditary Hemorrhagic Telangiectasia With Recurrent Epistaxis.
Compare the frequency of epistaxis and quality of life related to nasal bleeding in patients with HHT colonized with sataphylococo before and after being treated with mupirocin ointment.
Hereditary hemorrhagic telangiectasia is a vascular dysplasia characterized by the
development of mucocutaneous telangiectasia and arteriovenous malformations in organs such
as brain, lung, liver and tube digestivo. Is considered a rare disease, although It means
that there is a substantial underdiagnosis. The overall prevalence is 1/5000.
Approximately 60% of the general population hosts strains of Staphylococcus aureus (S.
aureus) intermittently and are called intermittent carriers, 20% represent persistent
carriers harboring the same strain of S. aureus and 20% of the population are never
carriers.
On this concept, one might think that HHT patients in whom there is an active and
pathological vascular remodeling that causes bleeding, and inflammation is a known activator
of abnormal angiogenesis; reducing an inflammatory factor as microbial through the
eradication of nasal S. aureus could be useful to reduce bleeding in this population,
directly impacting on quality of life.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05334017 -
Xylometazoline and Cocaine for Nasal Vasoconstriction
|
Phase 4 | |
Not yet recruiting |
NCT04519463 -
The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing
|
Early Phase 1 | |
Recruiting |
NCT01886768 -
Double Versus Single Pledget Nasal Anesthesia for Transnasal Endoscopy
|
N/A | |
Recruiting |
NCT00390663 -
A Prospective Randomised Controlled Trial of Management of Recurrent Nosebleeds in Children
|
Phase 4 | |
Suspended |
NCT04054687 -
Intranasal TXA for Anterior Epistaxis in the Emergency Department
|
Phase 2 | |
Completed |
NCT02285634 -
The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.
|
N/A | |
Completed |
NCT01485224 -
Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
|
Phase 2 | |
Completed |
NCT00793117 -
The Effect of Packing in Post Operative Management of FESS
|
Phase 4 | |
Recruiting |
NCT06259292 -
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
|
||
Recruiting |
NCT03850964 -
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05281952 -
Medico-economic Evaluation of Management Strategies for Severe Epistaxis
|
N/A | |
Completed |
NCT04279288 -
The Roles of Hilotherapy in the Management of Epistaxis and Nasal Fractures
|
N/A | |
Completed |
NCT03360045 -
Comparing Effectiveness of Merocel and Packing With Tranexamic Acid in the Management of Anterior Epistaxis
|
Phase 4 | |
Completed |
NCT03912051 -
Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting
|
N/A | |
Not yet recruiting |
NCT02677467 -
Correlation Between Epistaxis and Cardiovascular Disease
|
N/A | |
Completed |
NCT01314274 -
Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
Terminated |
NCT01051427 -
Control of Epistaxis With Surgiflo
|
N/A | |
Completed |
NCT00863356 -
Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis
|
N/A | |
Recruiting |
NCT05269849 -
Sirolimus for Nosebleeds in HHT
|
Phase 2 | |
Not yet recruiting |
NCT05343650 -
NOVAPAK Nasal Packing in Shellfish Allergic Patients
|
Phase 4 |